Measurement of Ejection Fraction by Cardiac Magnetic Resonance Imaging and Echocardiography to Monitor Doxorubicin-Induced Cardiotoxicity

Abstract

Doxorubicin is a standard treatment option for breast cancer, lymphoma, and leukemia, but its benefits are limited by its potential for cardiotoxicity. The primary objective of this study was to compare cardiac magnetic resonance imaging (CMRI) versus echocardiography (ECHO) to detect a reduction in left ventricular ejection function, suggestive of doxorubicin cardiotoxicity. We studied eligible patients who were 18 years or older, who had breast cancer or lymphoma, and who were offered treatment with doxorubicin with curative intent dosing of 240 to 300 mg/m² body surface area between March 1, 2009 and October 31, 2013. Patients underwent baseline CMRI and ECHO. Both imaging studies were repeated after four cycles of treatment. Ejection fraction (EF) calculated by both methods was compared and analyzed with the inferential statistical Student's t test. Twenty-eight eligible patients were enrolled. Two patients stopped participating in the study before undergoing baseline CMRI; 26 patients underwent baseline ECHO and CMRI. Eight of those 26 patients declined posttreatment studies, so the final study population was 18 patients. There was a significant difference in EF pre- and posttreatment in the CMRI group (p = 0.009) versus the ECHO group that showed no significant differences in EF (p = NS). It appears that CMRI is superior to ECHO for detecting doxorubicin-induced reductions in cardiac systolic function. However, ECHO is less expensive and more convenient for patients because of its noninvasive character and bedside practicality. A larger study is needed to confirm these findings.

Keywords

breast cancer - cardiac imaging - cardiac MRI - cardiotoxicity - doxorubicin - echocardiography - lymphoma

Note

This paper was presented at the International Congress of Angiology meeting held at Columbus, Ohio, in May, 2013.

• References

• 1 Takimoto CH. Topoisomerase interactive agents. In Devita VT, Hellman S, Rosenberg SA. , eds., Cancer Principles and Practice of Oncology. 7th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2005: 375-389
• 2 Von Hoff DD, Layard MW, Basa P. , et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91 (05) 710-717
• 3 Ueno M, Kakinuma Y, Yuhki K. , et al. Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. J Pharmacol Sci 2006; 101 (02) 151-158
• 4 Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 2002; 62 (16) 4592-4598
• 5 Ewer MS, Lippman SM, Type II. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23 (13) 2900-2902
• 6 Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 2008; 10 (05) 5
• 7 Wassmuth R, Lentzsch S, Erdbruegger U. , et al. Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-a pilot study. Am Heart J 2001; 141 (06) 1007-1013
• 8 Schiller NB, Shah PM, Crawford M. , et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography on standards, subcommittee on quantitation of two-dimensional echocardiograms. J Am Soc Echocardiogr 1989; 2 (05) 358-367
• 9 Chan J, Jenkins C, Khafagi F, Du L, Marwick TH. What is the optimal clinical technique for measurement of left ventricular volume after myocardial infarction? A comparative study of 3-dimensional echocardiography, single photon emission computed tomography, and cardiac magnetic resonance imaging. J Am Soc Echocardiogr 2006; 19 (02) 192-201
• 10 Hibberd MG, Chuang ML, Beaudin RA. , et al. Accuracy of three-dimensional echocardiography with unrestricted selection of imaging planes for measurement of left ventricular volumes and ejection fraction. Am Heart J 2000; 140 (03) 469-475
• 11 Plana JC, Galderisi M, Barac A. , et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014; 27 (09) 911-939
• 12 Walker J, Bhullar N, Fallah-Rad N. , et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. J Clin Oncol 2010; 28 (21) 3429-3436
• 13 Jacobs LD, Salgo IS, Goonewardena S. , et al. Rapid online quantification of left ventricular volume from real-time three-dimensional echocardiographic data. Eur Heart J 2006; 27 (04) 460-468 ; Rapid online
• 14 Avelar E, Strickland CR, Rosito G. Role of imaging in cardio-oncology. Curr Treat Options Cardiovasc Med 2017; 19 (06) 46
• 15 Gulati G, Heck SL, Ree AH. , et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 2016; 37 (21) 1671-1680
• 16 Tamene AM, Masri C, Konety SH. Cardiovascular MR imaging in cardio-oncology. Magn Reson Imaging Clin N Am 2015; 23 (01) 105-116
• 17 Bellenger NG, Burgess MI, Ray SG. , et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable?. Eur Heart J 2000; 21 (16) 1387-1396
• 18 Cardinale D, Colombo A, Bacchiani G. , et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015; 131 (22) 1981-1988
• 19 Avelar E, Truong QA, Inyangetor D. , et al. Effect of adjuvant chemotherapy on left ventricular remodeling in women with newly diagnosed primary breast cancer: a pilot prospective longitudinal cardiac magnetic resonance imaging study. J Thorac Imaging 2017; 32 (06) 365-369
• 20 Gaasch WH, Zile MR. Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry. J Am Coll Cardiol 2011; 58 (17) 1733-1740
• 21 Tan TC, Scherrer-Crosbie M. Cardiac complications of chemotherapy: role of imaging. Curr Treat Options Cardiovasc Med 2014; 16 (04) 296
• 22 Perez EA, Suman VJ, Davidson NE. , et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 2004; 22 (18) 3700-3704